Transplant Oncology: An Evolving Field in Cancer Care
Abstract
:Simple Summary
Abstract
1. Introduction
2. Concept and History of Transplant Oncology
2.1. Liver Transplantation for Hepatocellular Carcinoma
2.1.1. Milan Criteria
2.1.2. Beyond Milan Criteria
A. UCSF Criteria
B. Beyond UCSF Criteria
2.2. Liver Transplant for Non-Hepatocellular Carcinoma Tumors
2.2.1. Cholangiocarcinoma
A. Hilar Cholangiocarcinoma
B. Intrahepatic Cholangiocarcinoma
2.2.2. Hepatoblastoma
3. Liver Metastases
3.1. Neuroendocrine Tumor Liver Metastases
3.2. Colorectal Cancer
4. Emerging Concepts in Transplant Oncology
4.1. Immune Therapy in the Peri-Transplant Period
4.1.1. Pretransplant Bridging Therapy
4.1.2. Post-Transplant Palliative Therapy
4.2. Utility of Circulating Tumor DNA (ctDNA) for Cancer Minimal Residual Disease (MRD) Evaluation and Surveillance
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Kim, D.H.; Choi, S.H.; Park, S.H.; Kim, K.W.; Byun, J.H.; Kim, S.Y.; Lee, S.S.; Choi, J.I. The Liver Imaging Reporting and Data System tumor-in-vein category: A systematic review and meta-analysis. Eur Radiol. 2021, 31, 2497–2506. [Google Scholar] [CrossRef] [PubMed]
- Sapisochin, G.; Hibi, T.; Toso, C.; Man, K.; Berenguer, M.; Heimbach, J. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann. Surg. 2021, 273, 483–493. [Google Scholar] [CrossRef] [PubMed]
- Hibi, T.; Sapisochin, G. What is transplant oncology? Surgery 2019, 165, 281–285. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Balogh, J.; Victor, D., 3rd; Asham, E.H.; Burroughs, S.G.; Boktour, M.; Saharia, A. Hepatocellular carcinoma: A review. J. Hepatocell. Carcinoma 2016, 3, 41–53. [Google Scholar] [CrossRef] [Green Version]
- Society TILT. ILTS 2019 Consensus Conference: Transplant Oncology—The Future of Multidisciplinary Management. 2019. Available online: https://ilts.org/events/consensus-conference/ (accessed on 24 September 2021).
- Mazzaferro, V.; Regalia, E.; Doci, R.; Andreola, S.; Pulvirenti, A.; Bozzetti, F.; Montalto, F.; Ammatuna, M.; Morabito, A.; Gennari, L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996, 334, 693–700. [Google Scholar] [CrossRef]
- Hibi, T.; Shinoda, M.; Itano, O.; Kitagawa, Y. Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis 2014, 10, 241–249. [Google Scholar] [CrossRef] [Green Version]
- Daoud, A.; Soliman, K.; Teeter, L.; Ali, H.; Graviss, E.A.; Mogawer, S. Alpha-Fetoprotein as a Modifier of Anatomic Criteria for Transplantation of HCC Patients. Transplant. Proc. 2021, 53, 833–838. [Google Scholar] [CrossRef]
- Mazzaferro, V.; Citterio, D.; Bhoori, S.; Bongini, M.; Miceli, R.; De Carlis, L. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): A randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020, 21, 947–956. [Google Scholar] [CrossRef]
- Gorgen, A.; Muaddi, H.; Zhang, W.; McGilvray, I.; Gallinger, S.; Sapisochin, G. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can. J. Gastroenterol. Hepatol. 2018, 2018, 9531925. [Google Scholar] [CrossRef] [Green Version]
- Yao, F.Y.; Ferrell, L.; Bass, N.M.; Bacchetti, P.; Ascher, N.L.; Roberts, J.P. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002, 8, 765–774. [Google Scholar] [CrossRef]
- Mazzaferro, V.; Sposito, C.; Zhou, J.; Pinna, A.D.; De Carlis, L.; Fan, J. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018, 154, 128–139. [Google Scholar] [CrossRef] [Green Version]
- Sapisochin, G.; Goldaracena, N.; Laurence, J.M.; Dib, M.; Barbas, A.; Ghanekar, A. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016, 64, 2077–2088. [Google Scholar] [CrossRef] [Green Version]
- Silva, M.; Moya, A.; Berenguer, M.; Sanjuan, F.; Lopez-Andujar, R.; Pareja, E. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 2008, 14, 1449–1460. [Google Scholar] [CrossRef]
- Mehta, N.; Bhangui, P.; Yao, F.Y.; Mazzaferro, V.; Toso, C.; Akamatsu, N. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020, 104, 1136–1142. [Google Scholar] [CrossRef]
- Qu, Z.; Ling, Q.; Gwiasda, J.; Xu, X.; Schrem, H.; Beneke, J. Hangzhou criteria are more accurate than Milan criteria in predicting long-term survival after liver transplantation for HCC in Germany. Langenbeck Arch. Surg. 2018, 403, 643–654. [Google Scholar] [CrossRef]
- Notarpaolo, A.; Layese, R.; Magistri, P.; Gambato, M.; Colledan, M.; Magini, G. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J. Hepatol. 2017, 66, 552–559. [Google Scholar] [CrossRef]
- Durand, F.; Antoine, C.; Soubrane, O. Liver Transplantation in France. Liver Transpl. 2019, 25, 763–770. [Google Scholar] [CrossRef]
- DeOliveira, M.L.; Cunningham, S.C.; Cameron, J.L.; Kamangar, F.; Winter, J.M.; Lillemoe, K.D. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 2007, 245, 755–762. [Google Scholar] [CrossRef]
- Jarnagin, W.R.; Fong, Y.; DeMatteo, R.P.; Gonen, M.; Burke, E.C.; Bodniewicz, B.J. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 2001, 234, 507–517. [Google Scholar] [CrossRef]
- Jarnagin, W.R.; Ruo, L.; Little, S.A.; Klimstra, D.; D’Angelica, M.; DeMatteo, R.P. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies. Cancer 2003, 98, 1689–1700. [Google Scholar] [CrossRef]
- Kobayashi, A.; Miwa, S.; Nakata, T.; Miyagawa, S. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br. J. Surg. 2010, 97, 56–64. [Google Scholar] [CrossRef]
- Kosuge, T.; Yamamoto, J.; Shimada, K.; Yamasaki, S.; Makuuchi, M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann. Surg. 1999, 230, 663–671. [Google Scholar] [CrossRef]
- Rea, D.J.; Heimbach, J.K.; Rosen, C.B.; Haddock, M.G.; Alberts, S.R.; Kremers, W.K. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 2005, 242, 451–458. [Google Scholar] [CrossRef]
- Rea, D.J.; Munoz-Juarez, M.; Farnell, M.B.; Donohue, J.H.; Que, F.G.; Crownhart, B. Major hepatic resection for hilar cholangiocarcinoma: Analysis of 46 patients. Arch. Surg. 2004, 139, 514–523. [Google Scholar] [CrossRef]
- Su, C.H.; Tsay, S.H.; Wu, C.C.; Shyr, Y.M.; King, K.L.; Lee, C.H. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann. Surg. 1996, 223, 384–394. [Google Scholar] [CrossRef]
- Washburn, W.K.; Lewis, W.D.; Jenkins, R.L. Aggressive surgical resection for cholangiocarcinoma. Arch. Surg. 1995, 130, 270–276. [Google Scholar] [CrossRef]
- Murad, S.D.; Kim, W.R.; Harnois, D.M.; Douglas, D.D.; Burton, J.; Kulik, L.M. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012, 143, 88–98.e3. [Google Scholar] [CrossRef] [Green Version]
- De Vreede, I.; Steers, J.L.; Burch, P.A.; Rosen, C.B.; Gunderson, L.L.; Haddock, M.G. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000, 6, 309–316. [Google Scholar] [CrossRef]
- Ebata, T.; Mizuno, T.; Yokoyama, Y.; Igami, T.; Sugawara, G.; Nagino, M. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br. J. Surg. 2018, 105, 829–838. [Google Scholar] [CrossRef]
- Meza-Junco, J.; Montano-Loza, A.J.; Ma, M.; Wong, W.; Sawyer, M.B.; Bain, V.G. Cholangiocarcinoma: Has there been any progress? Can. J. Gastroenterol. 2010, 24, 52–57. [Google Scholar] [CrossRef]
- Casavilla, F.A.; Marsh, J.W.; Iwatsuki, S.; Todo, S.; Lee, R.G.; Madariaga, J.R. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J. Am. Coll. Surg. 1997, 185, 429–436. [Google Scholar] [CrossRef] [Green Version]
- Meyer, C.G.; Penn, I.; James, L. Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 2000, 69, 1633–1637. [Google Scholar] [CrossRef] [PubMed]
- Shimoda, M.; Farmer, D.G.; Colquhoun, S.D.; Rosove, M.; Ghobrial, R.M.; Yersiz, H. Liver transplantation for cholangiocellular carcinoma: Analysis of a single-center experience and review of the literature. Liver Transpl. 2001, 7, 1023–1033. [Google Scholar] [CrossRef] [PubMed]
- Robles, R.; Figueras, J.; Turrion, V.S.; Margarit, C.; Moya, A.; Varo, E. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann. Surg. 2004, 239, 265–271. [Google Scholar] [CrossRef]
- Hong, J.C.; Petrowsky, H.; Kaldas, F.M.; Farmer, D.G.; Durazo, F.A.; Finn, R.S. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J. Am. Coll. Surg. 2010, 212, 514–520. [Google Scholar] [CrossRef]
- Moris, D.; Kostakis, I.D.; Machairas, N.; Prodromidou, A.; Tsilimigras, D.I.; Ravindra, K.V. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS ONE 2019, 14, e0220527. [Google Scholar] [CrossRef] [Green Version]
- Hong, J.C.; Jones, C.M.; Duffy, J.P.; Petrowsky, H.; Farmer, D.G.; French, S. Comparative Analysis of Resection and Liver Transplantation for Intrahepatic and Hilar Cholangiocarcinoma: A 24-Year Experience in a Single Center. Arch. Surg. 2011, 146, 683–689. [Google Scholar] [CrossRef] [Green Version]
- Lunsford, K.E.; Javle, M.; Heyne, K.; Shroff, R.T.; Abdel-Wahab, R.; Gupta, N. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: A prospective case-series. Lancet Gastroenterol. Hepatol. 2018, 3, 337–348. [Google Scholar] [CrossRef]
- Panayotova, G.; Lunsford, K.E.; Latt, N.L.; Paterno, F.; Guarrera, J.V.; Pyrsopoulos, N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J. Gastrointest. Surg. 2021, 13, 392–405. [Google Scholar] [CrossRef]
- Bridgewater, J.; Galle, P.R.; Khan, S.A.; Llovet, J.M.; Park, J.W.; Patel, T. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 2014, 60, 1268–1289. [Google Scholar] [CrossRef] [Green Version]
- Sapisochin, G.; Facciuto, M.; Rubbia-Brandt, L.; Marti, J.; Mehta, N.; Yao, F.Y. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 2016, 64, 1178–1188. [Google Scholar] [CrossRef]
- Pham, T.A.; Gallo, A.M.; Concepcion, W.; Esquivel, C.O.; Bonham, C.A. Effect of Liver Transplant on Long-term Disease-Free Survival in Children with Hepatoblastoma and Hepatocellular Cancer. JAMA Surg. 2015, 150, 1150–1158. [Google Scholar] [CrossRef] [Green Version]
- Moris, D.; Tsilimigras, D.I.; Ntanasis-Stathopoulos, I.; Beal, E.W.; Felekouras, E.; Vernadakis, S. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery 2017, 162, 525–536. [Google Scholar] [CrossRef] [Green Version]
- Mazzaferro, V.; Pulvirenti, A.; Coppa, J. Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation? J. Hepatol. 2007, 47, 460–466. [Google Scholar] [CrossRef]
- Mazzaferro, V.; Sposito, C.; Coppa, J.; Miceli, R.; Bhoori, S.; Bongini, M. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases from Neuroendocrine Tumors. Am. J. Transplant. 2016, 16, 2892–2902. [Google Scholar] [CrossRef]
- Pavel, M.; Costa, F.; Capdevila, J.; Gross, D.; Kianmanesh, R.; Krenning, E. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016, 103, 172–185. [Google Scholar] [CrossRef]
- Hibi, T.; Rela, M.; Eason, J.D.; Line, P.D.; Fung, J.; Sakamoto, S. Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020, 104, 1131–1135. [Google Scholar] [CrossRef]
- Valderrama-Treviño, A.I.; Barrera-Mera, B.; Ceballos-Villalva, J.C.; Montalvo-Javé, E.E. Hepatic Metastasis from Colorectal Cancer. Euroasian J. Hepatogastroenterol. 2017, 7, 166–175. [Google Scholar] [CrossRef]
- Wong, M.C.; Huang, J.; Lok, V.; Wang, J.; Fung, F.; Ding, H. Differences in Incidence and Mortality Trends of Colorectal Cancer Worldwide Based on Sex, Age, and Anatomic Location. Clin. Gastroenterol. Hepatol. 2021, 19, 955–966.e61. [Google Scholar] [CrossRef]
- National Cancer Institute TS, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Colorectal Cancer. 2020. Available online: https://seer.cancer.gov/statfacts/html/colorect.html (accessed on 24 September 2021).
- Dueland, S.; Guren, T.K.; Hagness, M.; Glimelius, B.; Line, P.D.; Pfeiffer, P. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann. Surg. 2015, 261, 956–960. [Google Scholar] [CrossRef] [Green Version]
- Tveit, K.M.; Guren, T.; Glimelius, B.; Pfeiffer, P.; Sorbye, H.; Pyrhonen, S. Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. J. Clin. Oncol. 2012, 30, 1755–1762. [Google Scholar] [CrossRef]
- Dueland, S.; Syversveen, T.; Solheim, J.M.; Solberg, S.; Grut, H.; Bjornbeth, B.A. Survival Following Liver Transplantation for Patients with Nonresectable Liver-only Colorectal Metastases. Ann. Surg. 2020, 271, 212–218. [Google Scholar] [CrossRef]
- She, W.H.; Cheung, T.T. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl. Gastroenterol. Hepatol. 2016, 1, 34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abdel-Wahab, N.; Shah, M.; Suarez-Almazor, M.E. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE. 2016, 11, e0160221. [Google Scholar] [CrossRef] [PubMed]
- Tabrizian, P.; Florman, S.S.; Schwartz, M.E. PD-1 inhibitor as bridge therapy to liver transplantation? Am. J. Transplant. 2021, 21, 1979–1980. [Google Scholar] [CrossRef] [PubMed]
- De Bruyn, P.; Van Gestel, D.; Ost, P.; Kruse, V.; Brochez, L.; Van Vlierberghe, H. Immune checkpoint blockade for organ transplant patients with advanced cancer: How far can we go? Curr. Opin. Oncol. 2019, 31, 54–64. [Google Scholar] [CrossRef] [PubMed]
- Rammohan, A.; Reddy, M.S.; Farouk, M.; Vargese, J.; Rela, M. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet? Hepatology 2018, 67, 1166–1168. [Google Scholar] [CrossRef] [Green Version]
- Munker, S.; De Toni, E.N. Use of checkpoint inhibitors in liver transplant recipients. United Eur. Gastroenterol. J. 2018, 6, 970–973. [Google Scholar] [CrossRef] [Green Version]
- Abdel-Wahab, N.; Safa, H.; Abudayyeh, A.; Johnson, D.H.; Trinh, V.A.; Zobniw, C.M. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature. J. Immunother. Cancer 2019, 7, 106. [Google Scholar] [CrossRef]
- Ziogas, I.A.; Evangeliou, A.P.; Giannis, D.; Hayat, M.H.; Mylonas, K.S.; Tohme, S. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2402 Patients. Oncologist 2020, 26, e1036–e1049. [Google Scholar]
- Labgaa, I.; Villanueva, A.; Dormond, O.; Demartines, N.; Melloul, E. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers 2021, 13, 659. [Google Scholar] [CrossRef]
- De Rubis, G.; Rajeev Krishnan, S.; Bebawy, M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol. Sci. 2019, 40, 172–186. [Google Scholar] [CrossRef]
- Cai, Z.; Chen, G.; Zeng, Y.; Dong, X.; Li, Z.; Huang, Y. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma. Clin. Cancer Res. 2019, 25, 5284–5294. [Google Scholar] [CrossRef]
- Jiang, P.; Chan, C.W.; Chan, K.C.; Cheng, S.H.; Wong, J.; Wong, V.W. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl. Acad. Sci. USA 2015, 112, E1317–E1325. [Google Scholar] [CrossRef] [Green Version]
- Ono, A.; Fujimoto, A.; Yamamoto, Y.; Akamatsu, S.; Hiraga, N.; Imamura, M. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol. Gastroenterol. Hepatol. 2015, 1, 516–534. [Google Scholar] [CrossRef] [Green Version]
- Kasi, P.M.; Budde, G.; Dayyani, F.; Botta, G.P.; Diehl, A.; King, G.T. Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers. J. Clin. Oncol. 2021, 39 (Suppl. S15), 4103. [Google Scholar] [CrossRef]
- Labgaa, I.; Villacorta-Martin, C.; D’Avola, D.; Craig, A.J.; von Felden, J.; Martins-Filho, S.N. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018, 37, 3740–3752. [Google Scholar] [CrossRef]
- Liao, W.; Yang, H.; Xu, H.; Wang, Y.; Ge, P.; Ren, J. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget 2016, 7, 3740–3752. [Google Scholar] [CrossRef] [Green Version]
- Hann, H.W.; Jain, S.; Park, G.; Steffen, J.D.; Song, W.; Su, Y.H. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Res. 2017, 3, 105–111. [Google Scholar] [CrossRef] [Green Version]
Study | No. of HCC Patients | Note | Biomarkers | Outcomes |
---|---|---|---|---|
[67] | 46 | Treatment: Transplant Resection | ctDNA | Detection of ctDNA was associated with increased recurrence |
[65] | 34 | Treatment: TACE Resection RFA | ctDNA | ctDNA can detect minimal residual disease and predict survival |
[70] | 41 | 10 controls | TERT, TP53, and CTNNB1 | Detection of ctDNA predicted shorter recurrence-free survival |
[71] | 10 | Treatment: TACE Resection RFA | Methylation of GSTP1 and RASSF1A or TP53 mutation | Detecting ctDNA in urine was feasible and predicted |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Abdelrahim, M.; Esmail, A.; Abudayyeh, A.; Murakami, N.; Saharia, A.; McMillan, R.; Victor, D.; Kodali, S.; Shetty, A.; Nolte Fong, J.V.; et al. Transplant Oncology: An Evolving Field in Cancer Care. Cancers 2021, 13, 4911. https://doi.org/10.3390/cancers13194911
Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Saharia A, McMillan R, Victor D, Kodali S, Shetty A, Nolte Fong JV, et al. Transplant Oncology: An Evolving Field in Cancer Care. Cancers. 2021; 13(19):4911. https://doi.org/10.3390/cancers13194911
Chicago/Turabian StyleAbdelrahim, Maen, Abdullah Esmail, Ala Abudayyeh, Naoka Murakami, Ashish Saharia, Robert McMillan, David Victor, Sudha Kodali, Akshay Shetty, Joy V. Nolte Fong, and et al. 2021. "Transplant Oncology: An Evolving Field in Cancer Care" Cancers 13, no. 19: 4911. https://doi.org/10.3390/cancers13194911